4 Early-Stage Women’s Health Startups Closing Care Gaps

Why Belle Health stands out

Belle Health has paired early consumer traction with clinical evidence. It had close to 30,000 paying subscribers by June 2025, less than a year after launching its international app. Its eight-week cognitive behavioral therapy program has been evaluated through two randomized controlled studies with university partners. Belle Health also reports CE-marked Class I medical device status and is pursuing insurer reimbursement in Germany.

What Belle Health is building

Belle Health combines daily cycle and symptom tracking with an eight-week cognitive behavioral therapy program for severe premenstrual disorders. Its Belle Ring adds temperature, heart rate, heart rate variability, sleep and movement data against the menstrual cycle. The model links recurring engagement with a potential reimbursement route. That creates two ways to build value: a direct subscription relationship and a clinically supported product that could move into payer-funded care.

Why Dx4Life stands out

Dx4Life raised SEK 6.4 million in its first funding round and has filed for international patent protection. Founder Yvonne Lundberg Giwercman is a professor at Lund University and has led research in reproductive genetics for more than a decade. The product is supported by a peer-reviewed study of 1,466 women in which genotype-matched treatment was associated with a 40% cumulative live-birth rate, compared with 29% among non-genotyped controls. Dx4IVF also agreed with sequencing in 91 of 100 patient samples.

What Dx4Life is building

Dx4Life is developing Dx4IVF, a cheek-swab test designed to guide the choice of ovarian-stimulation hormone before IVF begins. The test identifies an FSH-receptor variant and returns a visible result in under an hour.

The commercial advantage is workflow fit. Fertility clinics already control the prescribing decision, so a same-appointment genetic result can slot directly into an existing treatment step and keep the care pathway simple.

Why Maman Biomedical stands out

Maman Biomedical completed an FDA Pre-Submission meeting that clarified the Maman Port regulatory pathway, and it has secured more than $500,000 in non-dilutive funding. Three patent families cover its hollow and dissolving microneedle formats. The startup has also held a sponsored residency at mHUB in Chicago, giving the team access to product-development infrastructure while it advances a device intended to work with established fertility medicines.

What Maman Biomedical is building

Maman Biomedical is developing a family of microneedle products for fertility treatment. Maman Port is a single-use device for existing injectable medicines, Maman Patch is designed for sustained hormone delivery, and Maman Sense is an earlier-stage monitoring concept. Maman Biomedical is focused on changing how patients receive established fertility drugs. That could reduce the burden of repeated injections while preserving familiar medications and clinical protocols.

Why Mothercore stands out

Mothercore reports that 70% of patients book a follow-up consultation after their first session. A partnership with Fertifa adds an employer-funded payment route, while five signed partner contracts extend distribution beyond direct self-pay.

The startup was selected for DigitalHealth.London’s Launchpad programme and is listed by Livi’s Health Hub as an online pelvic-floor physiotherapy partner.

What Mothercore is building

Mothercore provides one-to-one pelvic floor physiotherapy through video consultations with specialist clinicians. Patients can access care without a referral or clinic visit and receive an individualized treatment plan.

Its opportunity is primarily one of access and distribution. By combining self-pay, employer benefits and healthcare partnerships, Mothercore can reach patients who may otherwise face long waits or limited local specialist provision.